Tekla Life Sciences Investors

Tekla Life Sciences Investorsverified

HQL

Price:

$13.6

Market Cap:

$371.97M

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of b...[Read more]

Industry

Asset Management

IPO Date

1992-05-01

Stock Exchange

NYSE

Ticker

HQL

The Enterprise Value as of December 2024 (TTM) for Tekla Life Sciences Investors (HQL) is 371.97M

According to Tekla Life Sciences Investors’s latest financial reports and current stock price. The company's current Enterprise Value is 371.97M. This represents a change of 38.93% compared to the average of 267.73M of the last 4 quarters.

Tekla Life Sciences Investors (HQL) Historical Enterprise Value (quarterly & annually)

How has HQL Enterprise Value performed in the past?

The mean historical Enterprise Value of Tekla Life Sciences Investors over the last ten years is 353.99M. The current 371.97M Enterprise Value has changed 10.41% with respect to the historical average. Over the past ten years (40 quarters), HQL's Enterprise Value was at its highest in in the September 2021 quarter at 514.44M. The Enterprise Value was at its lowest in in the December 2014 quarter at -35266315.52.

Quarterly (TTM)
Annual

Average

353.99M

Median

423.67M

Minimum

-223114786.52

Maximum

505.94M

Tekla Life Sciences Investors (HQL) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Tekla Life Sciences Investors Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 21.59%

Maximum Annual Enterprise Value = 505.94M

Minimum Annual Increase = -305.33%

Minimum Annual Enterprise Value = -223114786.52

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024423.12M19.92%
2023352.83M0.58%
2022350.79M-30.67%
2021505.94M19.26%
2020424.23M21.59%
2019348.89M-23.48%
2018455.96M-0.47%
2017458.13M-305.33%
2016-223114786.52-150.35%
2015443.13M5.51%

Tekla Life Sciences Investors (HQL) Average Enterprise Value

How has HQL Enterprise Value performed in the past?

The current Enterprise Value of Tekla Life Sciences Investors (HQL) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

375.58M

5-year avg

411.38M

10-year avg

353.99M

Tekla Life Sciences Investors (HQL) Enterprise Value vs. Peers

How is HQL’s Enterprise Value compared to its peers?

Tekla Life Sciences Investors’s Enterprise Value is less than Tekla World Healthcare Fund (427.67M), less than Tekla Healthcare Opportunities Fund (796.21M), less than Royce Value Trust Inc. (1.85B), less than John Hancock Financial Opportunities Fund (826.72M), less than Tekla Healthcare Investors (796.34M), less than Flaherty & Crumrine Dynamic Preferred and Income Fund Inc. (672.66M), less than Cohen & Steers Infrastructure Fund, Inc (3.23B), less than Eaton Vance Tax-Advantaged Global Dividend Income Fund (1.79B), less than BlackRock MuniYield Fund, Inc. (476.16M), less than Eaton Vance Tax-Advantaged Dividend Income Fund (2.25B), less than Eaton Vance Tax-Managed Buy-Write Income Fund (443.56M), greater than Nuveen California Select Tax-Free Income Portfolio (83.16M), less than Cohen & Steers REIT and Preferred Income Fund, Inc. (1.46B), less than XAI Octagon Floating Rate & Alternative Income Term Trust (382.11M), less than Nuveen Preferred and Income Term Fund (685.26M), less than First Trust Intermediate Duration Preferred & Income Fund (1.67B), less than Flaherty & Crumrine Preferred Securities Income Fund Inc. (1.26B), less than Eaton Vance Risk-Managed Diversified Equity Income Fund (618.44M),

Build a custom stock screener for Tekla Life Sciences Investors (HQL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tekla Life Sciences Investors using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tekla Life Sciences Investors (HQL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tekla Life Sciences Investors or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Tekla Life Sciences Investors's Enterprise Value?

What is the highest Enterprise Value for Tekla Life Sciences Investors (HQL)?

What is the 3-year average Enterprise Value for Tekla Life Sciences Investors (HQL)?

What is the 5-year average Enterprise Value for Tekla Life Sciences Investors (HQL)?

How does the current Enterprise Value for Tekla Life Sciences Investors (HQL) compare to its historical average?